Quality Assessment for PCR-based Minimal Residual Disease in Lymphoma: 10 Years of Cross-laboratory Standardization Process Within the Fondazione Italiana Linfomi MRD Network

• Barbara Mantoan,
• Elisa Genuardi,
• Martina Ferrante,
• Irene Della Starza,
• Elena Ciabatti,
• Susanna Grassi,
• Lucia Anna De Novi,
• Marzia Cavalli,
• Claudia Mannu,
• Anna Gazzola,
• Riccardo Bomben,
• Massimo Degan,
• Beatrice Alessandria,
• Christiane Pott,
• Marie-Hélène Delfau-Larue,
• Ramon García-Sanz,
• Claudio Agostinelli,
• Valter Gattei,
• Sara Galimberti,
• Ilaria Del Giudice,
• Gianluca Gaidano,
• Marco Ladetto,
• Simone Ferrero,
• Daniela Drandi,
• on behalf of the Fondazione Italiana Linfomi (FIL) MRD Network

Affiliations

Barbara Mantoan

1 Department of Molecular Biotechnologies and health sciences, Hematology Division, University of Torino, Italy

Elisa Genuardi

1 Department of Molecular Biotechnologies and health sciences, Hematology Division, University of Torino, Italy

Martina Ferrante

1 Department of Molecular Biotechnologies and health sciences, Hematology Division, University of Torino, Italy

Irene Della Starza

2 Hematology, Department of Translational and Precision Medicine, Sapienza University of Roma, Italy

Elena Ciabatti

4 Division of Hematology, Department of Clinical and Experimental Medicine, Santa Chiara Hospital, Pisa, Italy

Susanna Grassi

4 Division of Hematology, Department of Clinical and Experimental Medicine, Santa Chiara Hospital, Pisa, Italy

Lucia Anna De Novi

2 Hematology, Department of Translational and Precision Medicine, Sapienza University of Roma, Italy

Marzia Cavalli

2 Hematology, Department of Translational and Precision Medicine, Sapienza University of Roma, Italy

Claudia Mannu

5 Hematopathology section, IRCCS, Azienda Ospedaliero-Universitaria di Bologna, University of Bologna, Italy

Anna Gazzola

5 Hematopathology section, IRCCS, Azienda Ospedaliero-Universitaria di Bologna, University of Bologna, Italy

Riccardo Bomben

6 Clinical and Experimental Onco-Hematology Unit, Centro di Riferimento Oncologico, I.R.C.C.S., Aviano, Italy

Massimo Degan

6 Clinical and Experimental Onco-Hematology Unit, Centro di Riferimento Oncologico, I.R.C.C.S., Aviano, Italy

Beatrice Alessandria

1 Department of Molecular Biotechnologies and health sciences, Hematology Division, University of Torino, Italy

Christiane Pott

7 Second Medical Department, University Hospital Schleswig-Holstein, Kiel, Germany

Marie-Hélène Delfau-Larue

8 Laboratoire d’immunologie biologique, hôpital Henri-Mondor, Créteil Cedex, France

Ramon García-Sanz

9 Division of Hematology, Servicio de Hematología, Hospital Universitario de Salamanca, Spain

Claudio Agostinelli

5 Hematopathology section, IRCCS, Azienda Ospedaliero-Universitaria di Bologna, University of Bologna, Italy

Valter Gattei

6 Clinical and Experimental Onco-Hematology Unit, Centro di Riferimento Oncologico, I.R.C.C.S., Aviano, Italy

Sara Galimberti

4 Division of Hematology, Department of Clinical and Experimental Medicine, Santa Chiara Hospital, Pisa, Italy

Ilaria Del Giudice

2 Hematology, Department of Translational and Precision Medicine, Sapienza University of Roma, Italy

Gianluca Gaidano

10 Division of Hematology, Department of Translational Medicine, Università del Piemonte Orientale, Novara, Italy

Marco Ladetto

10 Division of Hematology, Department of Translational Medicine, Università del Piemonte Orientale, Novara, Italy

Simone Ferrero

1 Department of Molecular Biotechnologies and health sciences, Hematology Division, University of Torino, Italy

Daniela Drandi

1 Department of Molecular Biotechnologies and health sciences, Hematology Division, University of Torino, Italy

on behalf of the Fondazione Italiana Linfomi (FIL) MRD Network